Enhanced peroxisome proliferator-activated receptor-γ expression in monocyte/macrophages from coronary artery disease patients and possible gender differences

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 2, 2009, Pages 531-538

  Amoruso, Angela ^a   Bardelli, Claudio ^a   Fresu, Luigia G ^a   Palma, Alessandra ^a   Vidali, Matteo ^a   Ferrero, Valeria ^b   Ribichini, Flavio ^b   Vassanelli, Corrado ^b   Brunelleschi, Sandra ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; MACROPHAGE; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CORONARY DISEASE; CYTOKINES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; PPAR ALPHA; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SEX CHARACTERISTICS;

EID: 70350443414     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.154419     Document Type: Article

References (40)

1. Amoruso A, Bardelli C, Gunella G, Fresu LG, Ferrero V, and Brunelleschi S (2007) Quantification of PPAR-gamma protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine. Life Sci 81:906-915. (Pubitemid 47374210)
2. Amoruso A, Bardelli C, Gunella G, Ribichini F, and Brunelleschi S (2008) A novel activity for substance P: stimulation of peroxisome proliferator- activated receptor-γ in human monocytes and macrophages. Br J Pharmacol 154:144-152. (Pubitemid 351620392)
3. Andreakos E, Sacre SM, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, Monaco C, Feldmann M, and Foxwell BM (2004) Distinct pathways of LPS-induced NF-κB activation and cytokine production in human myeloid and non-myeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood 103:2229-2237. (Pubitemid 38326242)
4. Babaev VR, Ishiguro H, Ding L, Yancey PG, Dove DE, Kovacs WJ, Semenkovich CF, Fazio S, and Linton MF (2007) Macrophage expression of peroxisome proliferator-activated receptor-κ reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 116:1404-1412. (Pubitemid 47417567)
5. Bardelli C, Gunella G, Varsaldi F, Balbo P, Del Boca E, Bernardone IS, Amoruso A, and Brunelleschi S (2005) Expression of functional NK1 receptors in human alveolar macrophages: superoxide anion production, cytokine release and involvement of NF-kappaB pathway. Br J Pharmacol 145:385-396. (Pubitemid 40896083)
6. Blake GJ and Ridker PM (2002) Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252:283-294. (Pubitemid 35253696)
7. Brown JD and Plutzky J (2007) Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115:518-533. (Pubitemid 46184203)
8. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, et al. (2001) A PPARκ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171. (Pubitemid 32162909)
9. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, et al. (2001) PPAR-α and PPAR-κ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58. (Pubitemid 32095642)
10. Collot-Teixeira S, Martin J, McDermott-Roe C, Poston R, and McGregor JL (2007) CD36 and macrophages in atherosclerosis. Cardiovasc Res 75:468-477.
11. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, et al. (2002) Reduction of atherosclerosis by the peroxisome proliferator activated receptor-α agonist fenofibrate in mice. J Biol Chem 277:48051-48057. (Pubitemid 35470751)
12. Duval C, Chinetti G, Trottein F, Fruchart JC, and Staels B (2002) The role of PPARs in atherosclerosis. Trends Mol Med 8:422-430.
13. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, and RECORD Study Group (2007) Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 357:28-38. (Pubitemid 47026732)
14. Jiang C, Ting AT, and Seed B (1998) PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86. (Pubitemid 28079219)
15. Lazar MA (2001) Progress in cardiovascular biology: PPAR for the course. Nat Med 7:23-24.
16. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, and Glass CK (2000) Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531. (Pubitemid 30666385)
17. Li AC and Palinski W (2006) Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Annu Rev Pharmacol Toxicol 46:1-39.
18. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 25:402-408. (Pubitemid 34164012)
19. Mandard S, Müller M, and Kersten S (2004) Peroxisome proliferator-activated receptor α target genes. Cell Mol Life Sci 61:393-416. (Pubitemid 38316578)
20. Manning PJ, Sutherland WH, Walker RJ, Williams SM, de Jong SA, and Berry EA (2008) The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals. Diabetes Res Clin Pract 81:209-215.
21. McGuire DK and Inzucchi SE (2008) New drugs for the treatment of diabetes mellitus: part I: thiazolidinediones and their evolving cardiovascular implications. Circulation 117:440-449.
22. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421.
23. Nicholson AC (2004) Expression of CD36 in macrophages and atherosclerosis. The role of lipid regulation of PPARγ signalling. Trends Cardiovasc Med 14:8-12.
24. Nissen SE and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471. (Pubitemid 46919772)
25. Osterud B and Bjorklid E (2003) Role of monocytes in atherogenesis. Physiol Rev 83:1069-1112.
26. Ricote M, Li AC, Willson TM, Kelly CJ, and Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82. (Pubitemid 28079218)
27. Ridker PM, Rifai N, Stampfer MJ, and Hennekens CH (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101:1767-1772. (Pubitemid 30213096)
28. Rotter V, Nagaev I, and Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes ans is, like tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777-45784. (Pubitemid 37432722)
29. Schupp M, Janke J, Clasen R, Unger T, and Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109:2054-2057. (Pubitemid 38620211)
30. Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T, and Kintscher U (2006) Regulation of peroxisome proliferator-activated receptor γ activity by losartan metabolites. Hypertension 47:586-589. (Pubitemid 43843880)
31. Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, Bond MG, de Faire U, Nilsson J, Eriksson P, et al. (2002) Plasma tumour necrosis factor-α and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 23:376-383. (Pubitemid 35204198)
32. Storka A, Vojtassakova E, Mueller M, Kapiotis S, Haider DG, Jungbauer A, and Wolzt M (2008) Angiotensin inhibition stimulates PPARγ and the release of visfatin. Eur J Clin Invest 38:820-826.
33. Teupser D, Mueller MA, Koglin J, Wilfert W, Ernst J, von Scheidt W, Steinbeck G, Seidel D, and Thiery J (2008) CD36 mRNA expression is increased in CD14 monocytes of patients with coronary heart disease. Clin Exp Pharmacol Physiol 35:552-556.
34. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, and Evans RM (1998) PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252. (Pubitemid 28180857)
35. Tordjman K, Bernal-Mizrachi C, Zemany L, Weng S, Feng C, Zhang F, Leone TC, Coleman T, Kelly DP, and Semenkovich CF (2001) PPAR-α deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 107:1025-1034. (Pubitemid 32323412)
36. Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, Werman A, Pories WJ, Caro JF, and Flier JS (1997) Peroxisome proliferator-activated receptor gene expression in human tissues. J Clin Invest 99:2416-2422.
37. Wang G, Zhang Z, Yu J, Zhang F, He L, Wei J, Mao J, and Wang X (2008) Antidiabetic rosiglitazone reduces soluble intercellular adhesion molecule-1 level in type 2 diabetic patients with coronary artery disease. PPAR Res doi: 10.1155/2008/548178.
38. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, Motoshima H, Taguchi T, Sonoda K, Kukidome D, et al. (2007) Statins activate peroxisome proliferator-activated receptor γ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 100:1442-1451. (Pubitemid 46834756)
39. tk;2Young SG and Fielding CJ (1999) The ABCs of cholesterol efflux. Nat Genet 22:316-318.
40. Zambon A, Gervois P, Pauletto P, Fruchart JC, and Staels B (2006) Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-α activators. Arterioscler Thromb Vasc Biol 26:977-986.